BACKGROUND:Quadrivalent human papillomavirus vaccine (QHPV) is > 95% effective in preventing infection with vaccine-type human papillomavirus. The safety and immunogenicity of QHPV are unknown in HIV-infected children. METHODS:HIV-infected children (N = 126)-age > 7 to < 12 years, with a CD4% ≥ 15-and on stable antiretroviral therapy if CD4% was < 25-were blindly assigned to receive a dose ofQHPV or placebo (3:1 ratio) at 0, 8, and 24 weeks. Adverse events were evaluated after each dose. Serum antibody against QHPV antigens was measured by a competitive Luminex immunoassay 1 month after the third QHPV dose. RESULTS: The safety profile of QHPV was similar in the 2 study arms and to that previously reported for QHPV recipients. QHPV did not alter the CD4% or plasma HIV RNA. Seroconversion to all 4 antigens occurred in > 96% of QHPV recipients and in no placebo recipients. Geometric mean titer was > 27 to 262 times greater than the seropositivity cutoff value, depending on the antigen, but was 30%-50% lower against types 6 and 18 than those of age-similar historical controls. CONCLUSIONS:QHPV was safe and immunogenic in this cohort of HIV-infected children. Efficacy trials are warranted.
RCT Entities:
BACKGROUND:Quadrivalent human papillomavirus vaccine (QHPV) is > 95% effective in preventing infection with vaccine-type human papillomavirus. The safety and immunogenicity of QHPV are unknown in HIV-infectedchildren. METHODS:HIV-infectedchildren (N = 126)-age > 7 to < 12 years, with a CD4% ≥ 15-and on stable antiretroviral therapy if CD4% was < 25-were blindly assigned to receive a dose of QHPV or placebo (3:1 ratio) at 0, 8, and 24 weeks. Adverse events were evaluated after each dose. Serum antibody against QHPV antigens was measured by a competitive Luminex immunoassay 1 month after the third QHPV dose. RESULTS: The safety profile of QHPV was similar in the 2 study arms and to that previously reported for QHPV recipients. QHPV did not alter the CD4% or plasma HIV RNA. Seroconversion to all 4 antigens occurred in > 96% of QHPV recipients and in no placebo recipients. Geometric mean titer was > 27 to 262 times greater than the seropositivity cutoff value, depending on the antigen, but was 30%-50% lower against types 6 and 18 than those of age-similar historical controls. CONCLUSIONS:QHPV was safe and immunogenic in this cohort of HIV-infectedchildren. Efficacy trials are warranted.
Authors: Raphael P Viscidi; Brad Snyder; Susan Cu-Uvin; Joseph W Hogan; Barbara Clayman; Robert S Klein; Jack Sobel; Keerti V Shah Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-01 Impact factor: 4.254
Authors: A B Moscicki; S Shiboski; J Broering; K Powell; L Clayton; N Jay; T M Darragh; R Brescia; S Kanowitz; S B Miller; J Stone; E Hanson; J Palefsky Journal: J Pediatr Date: 1998-02 Impact factor: 4.406
Authors: J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel Journal: Proc Natl Acad Sci U S A Date: 1995-12-05 Impact factor: 11.205
Authors: Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky Journal: Am J Epidemiol Date: 2003-02-01 Impact factor: 4.897
Authors: Paula Schuman; Suzanne E Ohmit; Robert S Klein; Ann Duerr; Susan Cu-Uvin; Denise J Jamieson; Jean Anderson; Keerti V Shah Journal: J Infect Dis Date: 2003-06-17 Impact factor: 5.226
Authors: Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin Journal: Lancet Date: 2004 Nov 13-19 Impact factor: 79.321
Authors: James L Klosky; Kathryn M Russell; Kristin E Canavera; Heather L Gammel; Jason R Hodges; Rebecca H Foster; Gilbert R Parra; Jessica L Simmons; Daniel M Green; Melissa M Hudson Journal: Cancer Prev Res (Phila) Date: 2013-08-27
Authors: Josephine M Norquist; Shazia S Khawaja; Cizely Kurian; T Christopher Mast; Kai-Li Liaw; Michael N Robertson; Barbara Evans; David Gutsch; Patricia Saddier Journal: Hum Vaccin Immunother Date: 2012-08-21 Impact factor: 3.452
Authors: Staci L Sudenga; B Nelson Torres; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim Van der Loeff; Louvina E Van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano Journal: J Infect Date: 2015-10-19 Impact factor: 6.072
Authors: Lars Toft; Martin Tolstrup; Martin Müller; Peter Sehr; Jesper Bonde; Merete Storgaard; Lars Østergaard; Ole S Søgaard Journal: Hum Vaccin Immunother Date: 2014-02-19 Impact factor: 3.452